Bristol Myers Squibb EPS - Earnings per Share 2010-2022 | BMY

Bristol Myers Squibb annual and quarterly earnings per share history from 2010 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Bristol Myers Squibb EPS for the quarter ending September 30, 2022 was $0.75, a 8.7% increase year-over-year.
  • Bristol Myers Squibb EPS for the twelve months ending September 30, 2022 was $3.07, a 228.99% decline year-over-year.
  • Bristol Myers Squibb 2021 annual EPS was $3.12, a 178.2% decline from 2020.
  • Bristol Myers Squibb 2020 annual EPS was $-3.99, a 298.51% decline from 2019.
  • Bristol Myers Squibb 2019 annual EPS was $2.01, a 33.22% decline from 2018.
Bristol Myers Squibb Annual EPS
2021 $3.12
2020 $-3.99
2019 $2.01
2018 $3.01
2017 $0.61
2016 $2.65
2015 $0.93
2014 $1.20
2013 $1.54
2012 $1.16
2011 $2.16
2010 $1.79
2009 $5.34
Bristol Myers Squibb Quarterly EPS
2022-09-30 $0.75
2022-06-30 $0.66
2022-03-31 $0.59
2021-12-31 $1.07
2021-09-30 $0.69
2021-06-30 $0.47
2021-03-31 $0.89
2020-12-31 $-4.43
2020-09-30 $0.82
2020-06-30 $-0.04
2020-03-31 $-0.34
2019-12-31 $-0.73
2019-09-30 $0.83
2019-06-30 $0.87
2019-03-31 $1.04
2018-12-31 $0.71
2018-09-30 $1.16
2018-06-30 $0.23
2018-03-31 $0.91
2017-12-31 $-1.40
2017-09-30 $0.51
2017-06-30 $0.56
2017-03-31 $0.94
2016-12-31 $0.53
2016-09-30 $0.72
2016-06-30 $0.69
2016-03-31 $0.71
2015-12-31 $-0.12
2015-09-30 $0.42
2015-06-30 $-0.08
2015-03-31 $0.71
2014-12-31 $0.01
2014-09-30 $0.43
2014-06-30 $0.20
2014-03-31 $0.56
2013-12-31 $0.43
2013-09-30 $0.42
2013-06-30 $0.32
2013-03-31 $0.37
2012-12-31 $0.57
2012-09-30 $-0.43
2012-06-30 $0.38
2012-03-31 $0.64
2011-12-31 $0.51
2011-09-30 $0.56
2011-06-30 $0.52
2011-03-31 $0.57
2010-12-31 $0.28
2010-09-30 $0.55
2010-06-30 $0.53
2010-03-31 $0.43
2009-12-31 $4.05
2009-09-30 $0.48
2009-06-30 $0.49
2009-03-31 $0.32
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $155.188B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00